Iovance Biotherapeutics Receives FDA Clearance for Next-Generation IL-12 Tethered TIL Therapy Trial
核心洞察
Iovance Biotherapeutics received FDA clearance to initiate a Phase 1/2 basket trial for IOV-5001, a next-generation IL-12 (搜索) tethered tumor infiltrating lymphocyte therapy targeting solid tumors (搜索).
The trial will enroll patients with advanced colorectal, triple-negative breast, and estrogen receptor-low breast cancers, representing over 100,000 U.S. deaths annually.
IOV-5001 is engineered to express IL-12 (搜索) only within tumors and tether it to cell surfaces to enhance efficacy while preventing systemic toxicity.
Iovance Biotherapeutics announced that the U.S. Food and Drug Administration has granted clearance for its investigational new drug application to proceed with a Phase 1/2 basket trial of IOV-5001, a next-generation interleukin-12 (搜索) tethered tumor infiltrating lymphocyte therapy. The trial will begin enrolling patients in the second half of 2026 to investigate the safety and efficacy of a one-time IOV-5001 treatment regimen without the use of IL-2.
The study will target patients with advanced colorectal cancer (搜索), triple-negative breast cancer (搜索), and estrogen receptor-low breast cancer (搜索), as well as other highly prevalent solid tumors (搜索) that collectively represent more than 100,000 U.S. deaths annually, according to Surveillance, Epidemiology, and End Results Program Cancer Stat Facts.
Novel Engineering Approach
IOV-5001 represents a significant advancement in TIL therapy design. The treatment is engineered to express IL-12 (搜索) only within the tumor microenvironment to enhance efficacy, particularly in immunologically cold tumors. Critically, the therapy tethers IL-12 to the TIL cell surface rather than allowing it to be released into the bloodstream, a design intended to optimize safety while maintaining therapeutic benefit.
This approach builds upon earlier IL-12 (搜索) TIL therapies that demonstrated promising clinical activity. Previous secreted IL-12 TIL therapy showed a 63% confirmed objective response rate in clinical studies, as reported by Zhang, Rosenberg and colleagues in Clinical Cancer Research.
"Proceeding into the clinical trial of IOV-5001 is a defining moment as we extend our TIL platform across additional prevalent solid tumors (搜索)," said Frederick Vogt, Ph.D., J.D., Interim Chief Executive Officer and President of Iovance. "By tethering IL-12 (搜索) to the TIL cell surface and targeting its activity inside the tumor, IOV-5001 is designed to activate cold tumors and open an entirely new frontier of massive opportunities for TIL cell therapy."
Preclinical Promise
In preclinical studies, IOV-5001 demonstrated stronger antitumor activity and a healthier, more durable T cell profile compared to unmodified TIL therapies. The tethered design is intended to deliver the antitumor benefits observed with earlier IL-12 (搜索) TIL therapies while avoiding the systemic toxicity that has limited previous approaches.
The therapy is designed to safely deliver significantly higher cell doses than previous generations, potentially expanding the therapeutic window for TIL-based treatments. IOV-5001 is specifically engineered to express IL-12 (搜索) only inside the tumor, where it remains anchored to the TIL cell surface rather than being released into systemic circulation.
Expanding TIL Platform
This development represents Iovance's expansion of its TIL platform into additional solid tumor types. The company's Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication, establishing Iovance as a leader in the TIL therapy space.
The Phase 1/2 basket trial design will allow the company to evaluate IOV-5001 across multiple tumor types simultaneously, potentially accelerating development timelines and providing broader insights into the therapy's clinical utility across different cancer types that have historically been challenging to treat with immunotherapy approaches.